Retatrutide and thiamine scientific references

Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial

Jastreboff AM, et al. · N Engl J Med, 389(6):514-526 · 2023

Original source ↗ · doi:10.1056/NEJMoa2301972 · PMID 37366315

What it supports

Foundational evidence that retatrutide (GIP/GLP-1/glucagon triple agonist) produces large dose-dependent weight loss (-24.2% at 12 mg, 48 weeks) in adults with obesity.

What it does not show

Does not establish long-term (>1 year) outcomes, cardiovascular benefit, or anything about retatrutide combined with thiamine.

Panacea interpretation · The foundational retatrutide efficacy reference — and explicit that nothing is known about retatrutide combined with thiamine.

Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA

Rosenstock J, et al. · Lancet, 402(10401):529-544 · 2023

Original source ↗ · doi:10.1016/S0140-6736(23)01053-X · PMID 37385280

What it supports

Phase-2 evidence in type 2 diabetes: HbA1c -2.02% and bodyweight -16.94% at 12 mg/36 weeks, superiority over dulaglutide 1.5 mg, and rationale for phase-3 dose selection.

What it does not show

Does not demonstrate phase-3-scale safety, durability beyond 36 weeks, or any micronutrient interaction.

Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise (TRANSCEND-T2D-1): a double-blind, randomised, phase 3 trial

Bajaj HS, et al. · Lancet, 407(10546):2402-2413 · 2026

Original source ↗ · doi:10.1016/S0140-6736(26)00967-0 · PMID 42250575

What it supports

First peer-reviewed phase-3 confirmation of retatrutide efficacy and tolerability (HbA1c -1.94%, weight -15.3% at 12 mg/40 weeks, NCT06354660).

What it does not show

Does not cover populations on background metformin/SGLT2i, cardiovascular outcomes, or combination formulations.

Panacea interpretation · The pivotal peer-reviewed phase-3 anchor for the molecule Rethiamine is built around.

Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial

Sanyal AJ, et al. · Nat Med, 30(7):2037-2048 · 2024

Original source ↗ · doi:10.1038/s41591-024-03018-2 · PMID 38858523

What it supports

Phase-2a evidence that retatrutide markedly reduces liver fat in MASLD, supporting the glucagon-agonism hepatic mechanism.

What it does not show

Does not show histological MASH resolution/fibrosis improvement at phase-3 scale or hard liver outcomes.

Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registrational clinical trials

Giblin K, et al. · Diabetes Obes Metab, 28(1):83-93 · 2026

Original source ↗ · doi:10.1111/dom.70209 · PMID 41090431

What it supports

Documents the design, populations, endpoints and dose-escalation scheme (2 mg start, stepwise to 4/9/12 mg) of the TRIUMPH phase-3 programme behind the 2025-2026 readouts.

What it does not show

Contains no efficacy results; design papers cannot support outcome claims.

Rationale, design and baseline characteristics of the TRANSCEND-CKD trial of retatrutide in patients with chronic kidney disease

Heerspink HJL, et al. · Nephrol Dial Transplant, 41(6):1058-1068 · 2026

Original source ↗ · doi:10.1093/ndt/gfaf230 · PMID 41160422

What it supports

Shows the retatrutide programme is being extended into chronic kidney disease, with the trial’s design and enrolled baseline population.

What it does not show

No results yet; does not demonstrate any renal benefit of retatrutide.

TRIUMPH-1 (NCT05929066); TRIUMPH-2 (NCT05929079); TRIUMPH-4 (NCT05931367); TRANSCEND-T2D-1 (NCT06354660); TRIUMPH-Outcomes (NCT06383390)

ClinicalTrials.gov, US National Library of Medicine. · Records current as of 2026-07-30 · 2026

Original source ↗

What it supports

Authoritative registration record of the retatrutide phase-3 programme (designs, enrolment, status: TRIUMPH-1/2/4 and TRANSCEND-T2D-1 completed; TRIUMPH-Outcomes ongoing).

What it does not show

Registry entries record design and status, not peer-reviewed results; topline figures cited on the site come from company announcements pending journal publication.

Retatrutide and lipid and metabolite profiles in participants with obesity with or without type 2 diabetes

Pearson MJ, et al. · J Clin Endocrinol Metab, dgag201 (online ahead of print, 2026 May 14) · 2026

Original source ↗ · doi:10.1210/clinem/dgag201 · PMID 42135195

What it supports

Mechanistic (metabolomic/lipidomic) evidence that retatrutide shifts fatty-acid-oxidation and insulin-resistance biomarker clusters toward improved metabolic health in both phase-2 populations.

What it does not show

Post-hoc exploratory analysis; does not prove clinical outcome benefits or guide dosing.

Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials

Pasqualotto E, et al. · Metabol Open, 24:100321 · 2024

Original source ↗ · doi:10.1016/j.metop.2024.100321 · PMID 39318607

What it supports

Independent pooled confirmation of phase-1/2 weight and metabolic effects of retatrutide across RCTs.

What it does not show

Pre-dates all phase-3 data; pooled effect sizes rely on early-phase, shorter trials.

Comparative effects of drugs for adults with overweight or obesity: systematic review and network meta-analysis

Nong K, et al. · BMJ, 394:e372161 · 2026

Original source ↗ · doi:10.1136/bmj-2026-372161 · PMID 42419792

What it supports

Independent comparative ranking of anti-obesity pharmacotherapies; places retatrutide among emerging agents with the largest expected weight reductions (13.1-14.6% at one year, very low to low certainty).

What it does not show

Retatrutide estimates are low-certainty and indirect; no head-to-head mortality or long-term safety conclusions for retatrutide.

New Drugs on the Block: Dietary Management and Nutritional Considerations During the Use of Anti-Obesity Medication

Pardali EC, et al. · Nutrients, 18(6):962 · 2026

Original source ↗ · doi:10.3390/nu18060962 · PMID 41901137

What it supports

Rationale for structured nutritional management (including micronutrient monitoring) during incretin-based therapy, whose GI adverse events can compromise intake and adherence.

What it does not show

Narrative review; does not quantify thiamine deficiency risk on GLP-1/GIP/glucagon agonists or test supplementation.

Panacea interpretation · The closest published anchor for retatrutide-associated nutritional vulnerability — monitoring rationale, not a demonstrated deficiency mechanism.

Thiamine (Vitamin B1) — An Essential Health Regulator

Kazmierczak-Baranska J, Halczuk K, Karwowski BT. · Nutrients, 17(13):2206 · 2025

Original source ↗ · doi:10.3390/nu17132206 · PMID 40647310

What it supports

Current review of thiamine biochemistry, deficiency states, and its regulatory roles in energy metabolism and nervous-system function — background for the B1 component.

What it does not show

Does not study thiamine co-formulated with any incretin drug or in obesity pharmacotherapy.

The importance of thiamine (vitamin B1) in humans

Mrowicka M, Mrowicki J, Dragan G, Majsterek I. · Biosci Rep, 43(10):BSR20230374 · 2023

Original source ↗ · doi:10.1042/BSR20230374 · PMID 37389565

What it supports

Review of thiamine’s role in carbohydrate metabolism, deficiency-related disease, and factors affecting thiamine status.

What it does not show

No interventional data; does not address thiamine dosing in combination injectable products.

Does thiamine supplementation affect heart failure? A systematic review and meta-analysis of randomized controlled trials

Syed ARS, et al. · Heart Lung, 61:37-45 · 2023

Original source ↗ · doi:10.1016/j.hrtlng.2023.04.011 · PMID 37126872

What it supports

Trial-level evidence base for thiamine supplementation effects on cardiac function (e.g., left ventricular ejection fraction) in heart failure.

What it does not show

Small, heterogeneous RCTs; does not demonstrate benefit in obesity/diabetes populations or with incretin therapy.

Freeze-drying: A flourishing strategy to fabricate stable pharmaceutical and biological products

Abla KK, Mehanna MM. · Int J Pharm, 628:122233 · 2022

Original source ↗ · doi:10.1016/j.ijpharm.2022.122233 · PMID 36183914

What it supports

Scientific basis for lyophilisation as the standard approach to stabilising peptide/biologic drug products, including formulation and process considerations relevant to a dual-layer lyophilisate.

What it does not show

General review; does not characterise any retatrutide or retatrutide-thiamine lyophilised formulation specifically.

Panacea interpretation · The pharmaceutical-science foundation beneath the dual-layer Peptourbillon™ concept.

Strategies of formulation and lyophilization process for sodium chloride-mannitol-protein-based products

Lin C, Zhang X, Jin Z, Guo J. · J Pharm Sci, 114(9):103671 · 2025

Original source ↗ · doi:10.1016/j.xphs.2025.01.007 · PMID 40021008

What it supports

Recent formulation-process guidance on bulking agents (mannitol/NaCl systems) and lyophilisation cycle design for protein products — directly relevant to multi-component lyophilisate design.

What it does not show

Model-system work; does not address peptide-small-molecule (e.g., vitamin) co-lyophilisation or device-layer separation.